{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:45:48Z","timestamp":1793936748637,"version":"4.8.0"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:00:00Z","timestamp":1223424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> We describe herein 98 hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) (refractory in 83) who received micafungin either alone (8 patients) or in combination with other licensed antifungal therapies (OLAT) (90 patients). Of the 8 monotherapy patients, 4 were failing OLAT, received <jats:italic>de novo<\/jats:italic> micafungin, or were intolerant to prior OLAT (2 patients each). Of the 90 patients treated with combination, 7 had <jats:italic>de novo<\/jats:italic> IA and 83 had refractory infection. Most patients (81) had pulmonary IA, 42 (43%) had graft\u2010versus\u2010host disease (GVHD), and 26 (27%) were neutropenic (absolute neutrophil count &lt;500\u2003cells\/mm<jats:sup>3<\/jats:sup>) at onset of treatment. Successful response was seen in 25\/98 (26%); an additional 12 patients achieved stable disease. Response was seen in 2\/9 (22%) in <jats:italic>de novo<\/jats:italic> treatment, 21\/87 (24%) in refractory patients, and 2\/2 (100%) in toxicity failure patients. Additionally, response was seen in 22 of the 90 (24%) patients treated with combination therapy, and in 3 of 8 (38%) patients who were treated with micafungin alone. No significant differences in responses were found based on type of HSCT, GVHD status, site of IA, or <jats:italic>Aspergillus<\/jats:italic> species, and no significant toxicity was seen. Micafungin was well tolerated, even at high doses, and is a reasonable option for treatment of IA in this high\u2010risk patient population.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2008.00349.x","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T19:18:14Z","timestamp":1223493494000},"page":"89-93","source":"Crossref","is-referenced-by-count":95,"title":["Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis"],"prefix":"10.1111","volume":"11","author":[{"given":"D.P.","family":"Kontoyiannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ratanatharathorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Laverdi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.F.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Facklam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kovanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Buell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-006-0025-x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0456"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22348"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.03.003"},{"key":"e_1_2_6_7_2","first-page":"7","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants","volume":"34","author":"Ascioglu S","year":"2002","journal-title":"an international consensus"},{"key":"e_1_2_6_8_2","first-page":"257","article-title":"Combination chemotherapy for invasive fungal infections","volume":"6","author":"Lewis RE","year":"2003","journal-title":"what laboratory and clinical studies tell us so far"},{"key":"e_1_2_6_9_2","first-page":"320","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients","volume":"81","author":"Singh N","year":"2006","journal-title":"a prospective, multicenter, observational study"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/423380"},{"key":"e_1_2_6_11_2","first-page":"2740","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies","volume":"110","author":"Caillot D","year":"2007","journal-title":"a randomized pilot study (Combistrat trial)"},{"key":"e_1_2_6_12_2","first-page":"1025","article-title":"Refractory aspergillus pneumonia in patients with acute leukemia","volume":"97","author":"Aliff TB","year":"2003","journal-title":"successful therapy with combination of caspofungin and liposomal amphotericin B"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11479"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21057"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/429333"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2008.00349.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2008.00349.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:56:40Z","timestamp":1696870600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2008.00349.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1399-3062.2008.00349.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2008.00349.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}